Irreversible and permanent damage develop immediately adjacent to the region of reduced cerebral blood perfusion in stroke patients. Currently, the proven thrombolytic treatment for stroke, tissue plasminogen activator, is only effective when administered within 3 h after stroke. These disease characteristics should be taken under consideration in developing any therapeutic intervention designed to widen the narrow therapeutic range, especially cell-based therapy. Over the past several years, our group and others have characterized the therapeutic potential of human umbilical cord blood cells for stroke and other neurological disorders using in vitro and vivo models focusing on the cells' ability to differentiate into nonhematopoietic cells including neural lineage, as well as their ability to produce several neurotrophic factors and modulate immune and inflammatory reaction. Rather than the conventional cell replacement mechanism, we advance alternative pathways of graft-mediated brain repair involving neurotrophic effects resulting from release of various growth factors that afford cell survival, angiogenesis, and anti-inflammation. Eventually, these multiple protective and restorative effects from umbilical cord blood cell grafts may be interdependent and act in harmony in promoting therapeutic benefits for stroke.
INTRODUCTION
time compounded by considerable risks such as intracranial hemorrhage and recurrent stroke (84) . Eventually, only 3-5% of stroke patients reach the hospital A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee within this therapeutic range and of those only 29% are eligible for r-tPA (80) , indicating that only a few stroke ranks stroke third among all other causes of death behind heart diseases and cancer in the US (96) . Each year patients have an opportunity at full restoration with rapid thrombolytic management. This unfortunate clini-about 600,000 new patients experience first stroke attacks, and 180,000 are recurrent attacks (96) . Among cal status clearly solicits new treatment modality with a wider therapeutic spectrum for stroke management. ischemic stroke survivors who were at least 65 years of age, 50% suffered from hemiparesis and 26% were
The ischemic stroke cell death cascades involve two major pathophysiological events. Glutamate excitotoxi-dependent on others to assist in their daily activities (96) . Currently, the only Food and Drug Administration-city develops in the ischemic tissue due to the sudden drop in oxygen and nutrients that begins immediately approved thrombolytic drug for acute ischemic stroke is recombinant-tissue plasminogen activator (r-tPA), which upon loss of blood flow (106). Subsequently, indirect inflammatory responses, such as generation of free oxy-acts by dissolving the blood clot in the vessel and restoring proper blood flow. However, there is only a 30-35% gen radicals and nitric oxide (24, 71) , activation of microglia within tissue hypoxia and necrosis (68, 107) , and success rate for recovery, even though r-tPA is administered within 3 h after the initial onset of an embolic invasion of other inflammatory cells by way of chemotaxis and leakage across the compromised blood-brain stroke (75, 84) , and the drug effectiveness decreases with barrier, contribute to disease progression (34, 41, 137) . granulocyte colony-stimulating factor stimulation, patients with malignancies are often unable to receive au-Thus, a more successful and effective treatment over current thrombolytic therapy must have a multifaceted tografts due to the risk of reinfection with tumorgenic cells (81) . The "timing" of intervention is critical for anti-inflammatory and neuroprotective ability to respond to all of these insults (80) as well as a longer range of successful stroke outcome, and therefore it may not be feasible to recover, manipulate, and process quality con-opportunity that increases the survival rate and improves functional recovery. This demand leads to exploration trolled autologous BM cells in a good manufacturing practice (cGMP) environment in time. of new therapeutic strategies targeting the restorative stage over the acute narrow therapeutic window, such as An efficacious substitute to BM cells is human umbilical cord blood (hUCB), which has already been used cell-based therapeutics designed to rescue against cell loss and simultaneously provide anti-inflammatory and/ clinically for several years to reconstitute BM and blood cell lineages in children with various hematological ma-or neurotrophic factors to combat the secondary neurodegeneration inherent in stroke.
lignant and nonmalignant diseases (105). Since the first hUCB cell transplantation to treat a 5-year-old child The advent of stem cells catapulted the field of cell therapy into the forefront of possible treatments for neu-who contracted Fanconi anemia in 1988 (44), a number of hUCB transplants have been performed worldwide, rological disorders, including stroke. Of particular interest is the availability of adult stem cells as donor cells many of them with unrelated donors (69, 118, 124) . Like BM, hUCB use has thus far been limited to hematopoi-for transplantation. Tissue-specific adult autologous stem cells such as neural stem cells (NSCs), bone marrow etic malignancies, marrow failure, and immunodeficiency disorders, but numerous reports reveal the many advan-(BM), or peripheral blood stem cells stand as attractive alternative sources for cell-based therapies for stroke tages of hUCB cells for cellular therapies compared to BM (81) . This includes the fact that hUCB cells, even (15) because they have the capacity for self-renewal and can generate cells other than themselves, resembling the from allogeneic origin, are immature, and produce a lower incidence of graft rejection, GvHD, and posttrans-multipotent features of primitive stem cells (i.e., embryonic or fetal origin). For example, adult NSCs can dif-plant infections (64, 118) . These characteristics have been attributed to higher numbers of immature progenitors in ferentiate into non-central nervous system derivatives, such as blood (9) or skeletal muscle cells (38) and vice hUCB compared to those of adult marrow stem cells, on the basis of telomere length (120). Moreover, the imma-versa. This plasticity of adult stem cells opens new approaches for their application in the treatment of various turity of cord blood stem cells and their immune naïveté have been implicated in the optimal effects of these cells neurodegenerative disorders. Nonetheless, clinical application of adult NSCs, like embryonic or fetal stem cells, for hematopoietic and somatic organ therapy.
The following sections present recent findings on the requires a careful preclinical evaluation of their safety and efficacy, as well as bioethical issues (27, 50) . Addi-specific "stemness" properties and therapeutic potential of hUCB as a unique, safe, and efficacious donor cell tional technical difficulties exist, such as ensuring purity of neural cultures and the harvesting of needed popula-for transplantation in stroke. tions for transplantation (91, 99) . Accumulating evidence has revealed the therapeutic potential of hematopoietic UNIQUE FEATURES OF hUCB stem cells in the treatment of not only blood-related dis-Cell Composition eases but also various unrelated disorders, even neurodegenerative diseases. Of these, BM is the current gold As a source of pluripotent stem cells, hUCB has been reported to be a source of hematopoietic stem cells, en-standard source of hematopoietic progenitor cells used to reconstitute blood lineages after myeloablative ther-dothelial cell precursors, mesenchymal progenitors, and multipotent/pluripotent lineage stem cells (7, 35, 63) . He-apy in a number of malignant and nonmalignant blood diseases (90) . Several reports have demonstrated that matopoietic stem cells from hUCB are rich in the most primitive cells and are capable of long-term reconstitu-BM stem cells can give rise to non-blood lineage tissues including neural cells (36, 86, 97) . Some disadvantages of tion of blood lineages (11, 79, 115) . While the number of myeloid progenitors in hUCB is similar to the number BM as donor cells, however, include the relative prolonged timing between procurement of and treatment in BM (11), hUCB cells have a greater colony-forming ability (78) and can be expanded in long-term cultures with BM cells (61), the considerable cost of the harvesting procedure (61), and the low availability of human in vitro using different growth factors and have longer telomeres than adult cells (120). Moreover, it has been leukocyte antigen (HLA)-matched donors with BM, which is crucial to avoid graft-versus-host disease (GvHD) revealed that hUCB transplants are better at restoring the host hematopoietic progenitor cell reservoir than (3) . Although these limitations can be avoided by transplantation of autologous BM or peripheral blood with adult BM stem cells (37) . Even a single hUCB sample can supply enough hematopoietic stem cells to provide of GvHD and viral transmission. Additionally, such cellular components could also allow for relatively flexible both short-and long-term engraftment (105).
Within the mononuclear fraction of hUCB, the com-donor-recipient matching requirements, hence leading to a shorter preparatory period for treatment (81) . Rocha ponent is primarily composed of lymphocytes and monocytes (87) . In an electron microscopic comparison of et al. found that GvHD incidence was significantly lower in children receiving hUCB transplants compared hUCB, peripheral blood, and BM cells, hUCB cells had the more immature morphology of myelomonocytic cells to BM recipients, when both sources were from an HLA-identical sibling (95) . Furthermore, even unrelated with small numbers of mature neutrophils (77). Compared with adult peripheral blood, hUCB resembles the HLA-mismatched UCB recipients have a lower GvHD incidence than HLA-identical BM recipients (94). B-cell population but with a lower absolute number of T cells (CD3 + ) and a higher CD4 + /CD8 + ratio (49, 87) .
Recently, we characterized in vitro two different subpopulations of mononuclear hUCB cells: adherent and Moreover, when comparing the characteristics of B-cell differentiation in vitro from hematopoietic progenitors floating (19) . A significant number of progenitor/stem and neural cell antigens were found to be expressed on (CD34 + ) between cord blood and peripheral blood, Bcell precursors differentiated from cord blood are more cells in the floating population, whereas the adherent cell population mainly contained lymphocytes (ϳ53%) immature (51) . The relative immunological immaturity of hUCB reveals a higher proportion of immature T cells expressing hematopoietic antigens. These results suggest that a nonhematopoietic subpopulation of cells exists (CB45RA + ), but decreased numbers of mature memory (CD45RO + ) (29, 49) and CD56 + cytotoxic (29) T cells within mononuclear hUCB cells and seems to have the potential to become neural cells. compared with other adult sources. Moreover, cord blood lymphocytes express cytokines and their receptors such
The mesenchymal stem cell (MSC) has also been found as a small fraction of UCB cells (30, 46, 133) . It as interleukin (IL)-2, IL-6, IL-7, tumor necrosis factorα (TNF-α), and interferon-γ (IFN-γ) at lower levels than was recently confirmed that MSCs and MSC-like progenitors can be isolated from amniotic fluid, placenta, in adult blood cells (45,139) and produce greater amounts of the anti-inflammatory cytokine IL-10 (45,89), which and Wharton's jelly (30) . MSCs derived from hUCB show impressive plasticity and differentiate into cells of downregulates expression of CD86 on dendritic cells (DCs), and may prevent initiation of the T-cell-mediated all germ-line derivatives (57, 70, 133) . Under appropriate conditions for culturing and differentiation, hUCB immune reaction (12). These increased levels of IL-10 may stimulate regulatory T cells, which in turn inhibit MSCs could differentiate into osteogenic cells and chondrogenic cells (66). After incubation in neural differenti-antigen-specific immune responses (5) . Monocytes in hUCB are also immature because hepatocyte growth ation medium, hUCB MSCs expressed the neural cell surface antigen A2B5, the neurofilament polypeptide NF factor (HGF) activates adult monocytes, but cord blood monocytes have no response to HGF, indicating they 200, the oligodendrocyte precursor marker 04, intermediate filament proteins characteristic of neural differenti-cannot induce integrin-α5 subunit or intercellular adhesion molecule-1, both of which are necessary for normal ation (nestin and vimentin), as well as the astrocyte marker glial fibrillary acidic protein (GFAP) and the function (59) . Moreover, hUCB monocytes have a reduced expression of HLA-DR compared to adult cells neural progenitor marker TuJ-1 (32). Additionally, supernatants from cultured hUCB MSCs promoted sur- (113) . In addition, cell subpopulations differ between adult blood and cord blood; for example, cord blood has vival of NT2N neural cells and peripheral blood mononuclear cells cultured under conditions designed to induce higher numbers of natural killer (NK) cells (29) , which are able to inhibit T-cell proliferation and reduce TNF-cell stress and limit protein synthesis (32). We also showed immunomodulatory effects of the hUCB MSCs α production (33). On the contrary, cytotoxicity from NK cells is lower in hUCB compared to adult blood after coculture with murine splenocytes (32). Taken together, these results indicate that hUCB MSCs also pos- (28) . DCs are the sentinel cells of the body and initiate immune responses within the lymph nodes. The DCs in sess multiple utilities that may contribute to their therapeutic potency in the treatment of neurological diseases. cord blood reflect lymphoid DCs that are most likely to be responsible for colonizing neonatal tissue, while there Ex Vivo Expansion and Surface Antigens are more myeloid DCs in adults (128) .
The lymphoid DCs induce anti-inflammatory T-helper 2 cell responses,
There is only a single chance to collect hUCB cells, and the number of mononuclear cells extracted from that which, along with the naive T cells, may promote downregulation of immune responses (4, 128) . These imma-isolated donation is finite (81) . Therefore, many researchers are currently interested in the ex vivo expansion of ture immunological properties in hUCB cells appear to result in a prolonged immunodeficient state after hUCB cord blood progenitor cells to provide a sufficient amount of stem cells for adult transplantation (72) . Expansion is transplantation (42, 114) . This leads to a low incidence essential in providing adequate dosage for both children CD34 for the selection and expansion of hematopoietic cells for transplantation (65, 135) . It has been shown that and adults, reducing the time to engraftment, thereby increasing success rate, as well as for recurrent therapy about 80% of CD34 + cells express CD133 and more than 97% of CD133 + cells are CD133 + /CD34 + in fresh cord in the event of initial graft failure (81) . Unfortunately, current methods of expanding hUCB cells do not pre-blood (48). Although CD133 + cells comprised 0.7% of the total mononuclear hUCB cells (74) , expansion of serve the quality of the hematopoietic progenitor cells through to the end product (56, 93) , but also cannot make CD133 + and CD133 + /CD34 + cells was significantly higher than that from the CD34 + cells (48). These find-up for the cells lost in the storage process, let alone augment them to a suitable dosing regimen (52, 73, 117, 134) .
ings suggest that CD133 + cells may be a more primitive hematopoietic progenitor/stem cell than CD34 + cells Moreover, simply globally multiplying the cells has been proven to not reduce the time to engraftment (56) . (39) . Furthermore, CD133 + cells have been identified in fetal brain and are considered to be NSCs (110, 119) , Instead, relative proportions of cell subpopulations that home to marrow, form colonies, and repopulate blood even though it is not yet known whether the CD133 + cells found in hUCB are phenotypically and functionally lineages are required (81) . Thus, recently, several studies about ex vivo expansion of different cell subpopula-identical to the NSCs found in fetal brain (81) . In the meantime, determining a definitive phenotype for hUCB tions of hUCB have been reported. Huang et al. (54) found that ex vivo expansion of hematopoietic stem MSC has proven to be controversial, unlike that of BM. Robinson (103) showed that the combination of that hUCB MSCs were negative for CD3, CD11b, CD19, CD34, and CD45 in culture (32). thrombopoietin with IL-3 used for expansion of megakaryocytic progenitors from cord blood not only resulted Proliferation and Differentiation Into Neural in optimal proliferation but also protected these cells and Other Lineages from apoptosis. Thus, these cells could be employed to supplement cord blood grafts and speed up platelet re-While embryonic primitive cells have highly proliferative potential and resistance to rejection and apoptosis, covery in transplant recipients (103) .
Meanwhile, there are major problems arising from which therefore may contribute to deleterious fibrosis and malignancies, cord blood stem cells are relatively the choice of an optimal stem cell population for ex vivo expansion and definition of the desired characteristics of quiescent under normal circumstances (116). Thus, the intrinsic proliferative and differentiatable potential of the expanded stem cells to be used for transplantation (102) . Expanded cells need to maintain telomerase length these quiescent stem cells needs to be stimulated by factors within the environment (23), without which the cells continuously in order to preserve their pluripotent capacity (134) . The telomerase activity of hematopoietic pro-do not proliferate unrestrained. Several in vitro and in vivo reports have been published showing the multipo-genitor cells is high and tends to be most active during proliferation (20) . Determining which cells should be tent nature of hUCB cells, including neural cells, thus helping to advance the potential usefulness of them in expanded is also tricky (81) . The level of maturity of a cell is identified by the presence of, or a lack of, a com-treating neurodegenerative diseases. Bicknese et al. stem cell-like cells. From these, a clonogenic line of hUCB NSCs, which expressed nestin and GFAP, was de-in hUCB can be defined as more primitive than those found in BM because a higher proportion of them are rived. In the presence of neuromorphogen/retinoic acid, 40% of the hUCB NSCs expressed βIII-tubulin and mi-negative for CD38, a marker for prelymphoid cells (14, 25) . Another human antigen, CD133, has also been crotubule-associated protein (MAP)-2 (neuronal marker), 30% expressed GFAP and S100β (astrocytic marker), identified as a marker for primitive hematopoietic progenitor/stem cells that may prove to be a substitute to and 11% expressed GalC (oligodendrocytic marker). Re-tinoic acid plus brain-derived neurotrophic factor has press neural antigens after in vitro exposure to defined media supplemented with a cocktail of growth and neu-also been shown to induce neural differentiation in hUCB NSC culture. During 7 days of coculture with neuromor-rotrophic factors (20) . When floating mononuclear hUCB cells were exposed to a neurogenic environment through phogens, rat astrocytes, or hippocampal slices, 80% of cells expressed βIII-tubulin and 64% coexpressed MAP-treatment with growth factors and neurotrophins, they had increased proliferation, expression of neural anti-2 (60). Goodwin et al. (46) demonstrated a subset of mononuclear cells from hUCB, which had been main-gens, and also survived longer in vivo (20) .
Once the cell type of interest has been determined tained in continuous culture for more than 6 months without antigen expression for hematopoietic differenti-and an adequate population of these cells has been obtained, the next step would be to transplant the cells. ation. When these cells were exposed to osteogenic, adipogenic agents, or epidermal and basic fibroblast growth This raises the question of what happens to the cells following transplantation and this is discussed in the factors (EGF and bFGFs), they expressed bone, fat, and neural markers, respectively. These data suggest that next section. hUCB contains a cell population that is capable of ex-Fate of Grafted Cells: What and Why? pressing antigens of multiple lineages, demonstrating that the plasticity of these cells makes them very impor-
The cells used for transplantation into humans are preferred to be of human origin. Although xenografting tant for cellular therapeutics with the goal of system repair (39) . Confirming the presence of a cell population of human cells into the rodent is a widely accepted research paradigm that often yields promising results (1, in hUCB with multipotent ability, McGuckin et al. (76) developed a negative immunomagnetic selection method 125), this presents a dilemma in in vivo research with human-originated stem cells. While hUCB cells show that depletes hematopoietic lineage marker-expressing cells from hUCB, thereby isolating a discrete lineage-the inability to generate cytotoxic T cells that respond to allogenic antigens, and to produce the proinflammatory negative stem cell population (0.1% of mononuclear hUCB). These selected lineage-negative hUCB cells ex-cytokines such as IFN-γ and TNF-α, transplantation of hUCB cells into adult or aged rat brains was associated panded into primitive nonadherent hematopoietic progenitors and simultaneously produced adherent cells with with vigorous rejection and strong immunosuppression was required to protect the graft (126). The limited sur-neuroglial progenitor cell morphology over 8 weeks. Gene expression analysis showed upregulation of primi-vival of the grafts in in vivo models possibly results from immune rejection. Therefore, recently we per-tive neuroglial progenitor cell markers for GFAP, nestin, musashi-1, and necdin.
formed studies using hUCB cells to determine their ability to survive in vivo and the effect of the immune re-Our group also revealed that the mononuclear hUCB cells under specific conditioned media including retinoic sponse on the survival by transplantation into the normal striatum of immunodeficient NOD SCID mice (125) . acid and nerve growth factor (NGF) expressed various neural markers for early neural precursors (musashi-1, First, in vitro, long-term culture (60-211 days) of hUCB cells resulted in several different populations of cells in-nestin, TuJ1), mature neurons (NeuN, MAP-2), and astrocytes (GFAP) (98) . Moreover, cells exposed to reti-cluding neuron-like cells that were positive for TuJ1 and nestin. Five days after transplantation of cells of this noic acid and NGF treatment increased TuJ1 and GFAP expression by approximately twofold (98) . Furthermore, neuronal phenotype, many differentiated hUCB cells expressing characteristic neuronal proteins were detected. Zigova et al. (138) showed that TuJ1 and GFAP immunopositive cells from hUCB mononuclear cells after However, at 1 month postgrafting, hUCB cells were no longer detected without evidence of T-cell-mediated re-treatment with retinoic acid and NGF survived in the subventricular zone of the rat neonatal forebrain. Addi-jection, such as CD4 and CD8 lymphocytes and activation of microglia and astrocytes (125) . These findings tionally, we have demonstrated that in standard growth medium such as Dulbecco's modified Eagle medium suggest that the disappearance of implanted cells was not due to a T-cell-mediated immune response. The (DMEM), mononuclear hUCB cells also express neural markers, such as nestin, TuJ1, MAP-2, and GFAP (40).
hUCB cells can survive for long periods of time in vitro and they can also exhibit neural characteristics depen-Interestingly, at 2 weeks after plating, colocalization of nestin, MAP-2, and various cytoplasmic expressions of dent on their environmental conditions, but the same does not appear to be true in vivo even though the cause TuJ1 by the cells was observed. Moreover, the increased number of cells expressing CD133 antigen after 7 days of this discrepancy is unclear (125) . A number of factors, such as the donor cell's condition and the recipi-in culture probably gives rise to cells that show immature and mature neural characteristics at the same time ent's environment, might simultaneously affect survival of the transplanted cells. (39) . Recently, similar to the above studies, we have examined the ability of mononuclear hUCB cells to ex-In summary, on the basis of several previous studies in vitro and in vivo, hUCB cells, due to their unique and NeuN. On the other hand, our group compared the efficiency of intravenous versus intrastriatal transplanta-primitive nature and ability to differentiate or become various lineages of cells including neural, may be a use-tion of mononuclear hUCB cells to evaluate which produced the greatest behavioral improvements in rats with ful target for cell-based therapies requiring either the replacement of individual cell types and/or provision of permanent MCAO (129) . Spontaneous activity (MCAOlesioned animals become significantly hyperactive) sig-missing materials in neurological disorders.
nificantly decreased when cells were transplanted 24 h PRECLINICAL STROKE RESEARCH after stroke compared with control animals. Behavioral ON TRANSPLANTATION OF HUMAN improvement, as measured by spontaneous activity, was UMBILICAL CORD BLOOD CELLS similar with both cell delivery routes. However, in the step test at 2 months after transplantation, significant im-As mentioned, although the timing to begin treatment for stroke is crucial (39) , the therapeutic window of cur-provements were found only after intravenous delivery of the hUCB cells. Also, in the passive avoidance test, rent stroke treatment is still restrictive. Many patients outside of this window suffer from irreversible sequela. transplanted rats learned the task faster than nontransplanted ones. These results suggest that intravenous injec-This current circumstance has brought serious consideration to the exploration of new therapeutic interventions tion of mononuclear hUCB cells may be more effective than direct striatal implantation in producing long-term such as a cell-based therapy. Using adult BM mesenchymal stem cells, functional improvement has been dem-functional benefits to the stroke animal. Next, we focused on the dose effect of mononuclear hUCB cells on onstrated in a rodent stroke model (16, 18, 22, 100) . While it has been reported that transplanted cells could suc-the behavioral recovery and infarct volume in MCAO rats (121) . Twenty-four hours after MCAO, rats were cessfully migrate to areas of ischemic infarcts and differentiate into neuronal and glial cell types, recently Chopp intravenously infused with 10 4 up to 3-5 × 10 7 mononuclear hUCB cells. At 4 weeks after transplantation, there and collegues suggested that recovery mechanisms are likely to be due to trophic factors released by cells that was a significant recovery in behavior, when 10 6 or more hUCB cells were delivered. Infarct volume mea-may promote endogenous neurogenesis, angiogenesis, and axogenesis rather than a result of neuronal replace-surements showed an inverse relationship between cell dosage and injured volume, which reached significance ment (26, 88, 101, 136) . Transplanted hematopoietic stem cells (CD34 + ), which were isolated from peripheral at the higher doses of mononuclear hUCB cells. These results revealed an important dose relationship between blood, also could differentiate into neural lineage cells and induce angiogenesis, in conjunction with improve-introduced implanted cells, behavioral improvement, and neuronal sparing, using intravenous mononuclear ment of the neurological impairment in a rodent stroke model (31, 104) .
hUCB cell injection in the MCAO model. In addition to route and dosage, determining the ther-The In Vivo Potential of Human Umbilical Cord apeutic window of cell transplantation for stroke is a Blood Cells major concern in the preclinical research field as well as for clinical application. Our research group attempted to hUCB is another promising source of multipotential stem cells that has shown affirmative effects in in vivo determine the optimal time to administer hUCB cells after stroke. Initially, in an in vitro assay system, the studies for the treatment of stroke. Chen et al. (17) showed that the intravenous administration of mononuclear hUCB migration capability of mononuclear hUCB cells according to the time after stroke was investigated (82) . This cells at 24 h or 7 days after middle cerebral artery occlusion (MCAO) significantly improved neurological func-assay revealed an increased migratory activity of mononuclear hUCB cells towards both the hippocampal and tion in a rat model. On histological examination, mononuclear hUCB cells were found mainly in the cortex and striatal extracts harvested at 24-72 h after stroke. Furthermore, the extracts possessed increased levels of cyto-striatum of the injured hemisphere in the ischemic boundary zone, whereas few cells were observed in the contra-kine-induced neutrophil chemoattractant-1 (CINC-1) and monocyte chemoattractant protein-1 (MCP-1) at 48 h lateral side. Some of the implanted mononuclear hUCB cells were immunoreactive for the endothelial cell marker after MCAO, suggesting participation of these substances in the cell migration. Further analysis of the is-FVIII (8%), as well as GFAP (6%), MAP-2 (3%), and NeuN (2%) by immunohistochemistry (17) . Using a chemic extracts showed that growth-regulated oncogene/CINC-1 (the rat equivalent of human IL-8) and nonhematopoietic cell line derived from hUCB, Xiao et al. (132) also observed a decrease in infarct volume after MCP-1 were expressed in a time-dependent pattern similar to that of the migration assays. The results from this intravenous transplantation into rats with ischemic brain injury. Histological examination showed that some of study are promising in that the current 3-h therapeutic window for the treatment of stroke victims, using ap-the transplanted cells were colocalized for human nuclei proved anticoagulant treatment, may be extended with potential anti-inflammatory effects of UCB therapy may be one of the mechanisms that protect against neuronal the use of mononuclear hUCB cell therapy to 24-72 h poststroke event. Also, the chemokines present in the death. In continuing studies, we found that, following MCAO, the rat's spleen size was reduced concomitantly supernatant could provide a sound starting point for examining the mechanisms responsible for the in vivo mi-with their CD8 + T-cell counts (123). Interestingly, MCAOinduced spleen size reduction correlated with the extent gration of mononuclear hUCB cells after stroke induction (82) . More recently, we demonstrated that, in vivo, of ischemic damage; however, hUCB cell treatment rescued the spleen weight, splenic CD8 + T-cell counts, as the hUCB treatment window is also narrow even though it is longer than thrombolytic agents. When we systemi-well as significantly reducing the amount of brain injury. Additionally, splenocyte proliferation assays demon-cally administered the hUCB cells at times ranging from 3 h to 30 days post-MCAO, maximal improvements strated that hUCB cell treatment opposed MCAO-associated T-cell proliferation by increasing the production were observed with treatment at 48 h (80) . These results might suggest that it is not critical for the cells to be of IL-10 while decreasing IFN-γ (123). Recently, we investigated the expression of cytokines and chemokines present indefinitely after transplantation, but that they are actually only needed within a very short time frame produced by hUCB cells under various culturing conditions (83). The heterogeneous cells from mononuclear to either appropriately prime the immune system or provide other secretory products to cells within the brain in fractions of hUCB consistently produced a variety of chemokines and cytokines when grown in various cul-order to confer therapeutic effects (80) .
ture conditions, but in particular, IL-8, MCP-1, and IL-Mechanisms Underlying Recovery Beyond 1α. They are produced more extensively than any other Neural Differentiation chemokines in the human body, especially in the brain, and have been implicated as the first line of defense in Cell replacement had been believed to be the main mechanism responsible for the functional recovery after the inflammatory reaction. These findings support the idea that inflammatory modulation from hUCB trans-transplantation on the basis of accumulating results of hUCB cells expressing neural phenotypes and providing plantation may be partially responsible for the functional improvements seen in animal models of injury, includ-behavioral improvement (40, 47, 98, 132, 138) , even though few cord blood cells are present in the ischemic region ing stroke.
A second potential mode of action is neovasculariza-compared to the number of infused cells (21, 121, 122, 129, 130) . However, there has been increasing evidence tion around ischemic tissue, promoted by hUCB. Angiogenesis is an important healing process of wounds in-of the multifaceted therapeutic effects of hUCB such as neurotrophic, angiogenic, and anti-inflammatory actions, cluding tissue ischemia, and it can attenuate local tissue ischemia and improve clinical outcomes (67) . Further-beyond the ability of transdifferentiation into neural lineage, in the MCAO stroke model (Fig. 1) . These effects more, angiogenesis appears to promote neurogenesis in neurological disease (92, 112) . There is accumulating more likely come from the trophic and other factor-releasing capabilities of hUCB (10) . Recently, it has been re-data that transplantation of hUCB cells induce neovascularization, followed by functional improvement in the vealed that mononuclear hUCB-derived neuronal progenitor cells decreased free radicals and induced antioxidants animal ischemic disease model (53, 62) . VEGF was increased in the experimental group (53) even though it and neurotrophic factors such as NGF, vascular endothelial growth factor (VEGF), and bFGF in an oxygen and was unclear whether transplanted hUCB cells directly released it or stimulated other cells for indirect secretion. glucose deprivation insult model (2) .
Initially, we focused on the anti-inflammatory action UCB not only contains high numbers of CD34 + endothelial progenitors cells (EPCs), which can give rise to ma-of hUCB cells. Vendrame et al. (122) demonstrated that there was an increase in the number of CD45 + /CD11b + ture endothelial cells and induce angiogenesis in ischemic tissues (85), but mononuclear cells (55) or MSCs (30) (microglia/macrophage) and CD45 + /B220 + (B cell) cells in the brain of rats with permanent MCAO, whereas mo-of UCB also can differentiate into EPCs. Taguchi et al. (109) demonstrated that CD34 + cells derived from hUCB nonuclear hUCB cell transplantation significantly decreased the number of these cells. The reduction in the induced angiogenesis, followed by endogenous neurogenesis in a mouse stroke model. Ding et al. (30) re-number of CD45 + /CD11b + cells after transplantation of hUCB cells is particularly interesting because chronic vealed that hUCB MSCs differentiated into glial, neuronal, and vascular endothelial cells as well as promoted microgliosis is thought to mediate neuronal damage, not only in ischemic injury but also in other neurodegenera-the formation of new vessel angiogenesis in the rat stroke model. Recently, we found that animals that re-tive diseases such as Parkinson's disease (107, 111) . The hUCB treatment also decreased the proinflammatory cy-ceived the monocyte/macrophage (CD14 + )-depleted hUCB preparation performed significantly to a lesser degree tokines such as TNF-α and IL-1β (122) . Therefore, the than those receiving the other hUCB cells (stem cell-, creased in the ischemic hemisphere of rat brain, and significantly promoted hUCB cell migration compared to T-cell-, B-cell-depleted, and whole mononuclear fraction of cord blood) in a rat stroke model (131) . These the contralateral side (58) . Also chemokine receptors were constitutively expressed on the surface of hUCB results suggest that monocyte/macrophage is critical to hUCB-induced recovery following stroke. Monocytes cells. The hUCB cell migration was neutralized with polyclonal antibodies against MCP-1 or MIP-1α. These have been known to play a key role in inducing angiogenesis under abnormal conditions such as ischemia and results suggested that the increased host chemokines in the ischemic area can bind surface receptors on exoge-tumor (108). Thus, these findings imply that transplantation of monocyte-depleted hUCB does not induce angio-nous hUCB, and attract systemically delivered hUCB cells into the central nervous system. genesis properly, and in turn, cannot improve neurological dysfunction.
In conclusion, stroke involves a complicated cascade of inflammatory events that eventually lead to a signifi-A third benefit of hUCB cells is their apparent migration following implantation to ischemic regions of the cant necrotic area adjacent to the obstructed vasculature. This cascade is time dependent, and when hUCB cells brain. We recently showed in vivo that several chemokines increase in the ischemic brain area (58) . MCP-are administered intravenously or intraparenchymally 48 h following stroke onset, they can prevent impending 1 and macrophage inflammatory protein (MIP-1α) are implicated in bloodstream monocyte infiltration into tis-neural cell crisis. The transplantation of hUCB cells most likely inhibits the apoptotic cascade, induces en-sues under pathological conditions (6, 43) . We found that MCP-1 and MIP-1α expression was significantly in-dogenous and/or exogenous neurogenesis, and modu- 
